Abstract:1545 Purpose: To investigate the in vivo imaging characteristics of a novel tau tracer ((S)-1-(4-(6-(dimethylamino) naphthalen-2-yl)phenoxy)-3-fluoropropan-2-ol,18F-S16) in humans and evaluate its performance in identifying AD patients from healthy controls (HCs) as compared with 18F-THK5317. Methods: The study cohort consisted of 6 AD, 1 FTLD, 1 PSP, 1 DLB, 6 HCs and 2 young volunteers. While dynamic PET was performed over a period of 90 min after injection in 1 AD, 6 HCs and 2 young volunteers, static images were acquired in all subjects from 40 min to 60 min after tracers’ administration. All PET data were co-registered to the corresponding MRI data. The time-activity curves of standardized uptake value (SUV) and SUV ratios (SUVRs) were extracted from regions of interested based on the AAL atlas. Logan graphical analysis was performed for quantification of distribution volume ratios (DVRs). Cerebellum was used as the reference region to calculate DVRs and SUVRs. SUVRs derived from 70-90 min and 40-60min were regressed onto DVR to assess the quantitative accuracy of SUVR. Two-sample t-test was performed for the voxel-based analyses of both tracers to assess their uptake differences between populations. Results: Both tracers were distributed to the brain rapidly but the clearance of 18F-S16 was slower than 18F-THK5317 at 90 min acquisition. The AD patient showed increased cortical 18F-S16 binding (e.g., the medial temporal cortex), which was in contrast to a minimal accumulation of tracers seen in the young volunteers. Regional SUVR of both tracers’ time courses showed differences between groups in medial temporal cortex, lateral temporal cortex and occipital cortex. But the SUVR of 18F-S16 was still increasing at 90 min in very high-binding regions. Regression outcome of SUVR70-90min onto DVR performed better than SUVR40-60min. As to images, 18F-S16 displayed higher grey matter but lower white matter uptake than 18F-THK5317 in controls. In comparative studies, the cortical average SUVR of 18F-THK5317 was 1.32 ± 0.10 for AD versus 1.15 ± 0.05 for HCs (F = 5.91, P < 0.05), and for 18F-S16, that was 1.20 ± 0.08 versus 1.14 ± 0.06, respectively (F = 3.17, P < 0.05) (Table 1.). In voxelwised analysis, AD patients showed significant increased cortical 18F-THK5317 binding in diffused bilateral cortical regions; 18F-S16 displayed increased abnormal radioactive retention in bilateral lateral temporal cortex, occipital cortex and right frontal cortex (Figure 1.). The patterns of uptake of both tracers were similar in FLTD and PSP patients, which were observed increased radioactive retention in the anterior temporal cortex, the globus pallidus and midbrain, respectively. No obvious abnormal uptake was found in the DLB patient. Conclusions: A significant difference in 18F-S16 uptake between AD and HCs in cortical regions especially from 40-60 min after the tracer administration and elevated 18F-S16 retention was observed in where tau pathology frequently occurred in patients with PSP, thus 18F-S16 might be a promising tau-tracer for PET imaging. But quantification strategies for 18F-S16 need to be well evaluated with longer scan duration, such as 180min, in view of its slower clearance from brain.

Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer’s Disease

In Vivo Imaging of Neurofibrillary Tau PET Radioligand 18F-S16 in Comparison with 18F-THK5317 in Alzheimer's Disease

In Vivo Imaging of Tau Deposition in Alzheimer’s Disease Using Both [18F]-THK5317 and [18F]-S16: A Pilot Human Study

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

Novel Β-Amyloid PET Imaging Study of [18F]92 in Patients with Cognitive Decline

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification

Synthesis and Bioevaluation of 2-Styrylquinoxaline Derivatives As Tau-PET Tracers.

Design, Synthesis, and Preliminary Evaluation of [18F]-Aryl Flurosulfates PET Radiotracers Via SuFEx Methods for Β-Amyloid Plaques in Alzheimer’s Disease

Preclinical and Clinical Study on [18F]DRKXH1: a Novel Β-Amyloid PET Tracer for Alzheimer’s Disease

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer's disease

Evaluation of a Novel PET Tracer [18F]-Florbetazine for Alzheimer's Disease Diagnosis and (3-Amyloid Deposition Quantification

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

An Automated Radiosynthesis of (S)-[18F]28 for PET Imaging of Alzheimer's Disease

Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives As Potential Tau Imaging Agents.

Synthesis and Preclinical Evaluation of Diarylamine Derivative As Tau-PET Radiotracer for Alzheimer’s Disease

Synthesis and Preclinical Evaluation of 2-(4-[18f]fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([18F]FPND-4): an Aza-Fused Tricyclic Derivative As Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging.